tiprankstipranks
Trending News
More News >
Becton Dickinson And Company (BDX)
NYSE:BDX

Becton Dickinson (BDX) AI Stock Analysis

Compare
1,967 Followers

Top Page

BD

Becton Dickinson

(NYSE:BDX)

68Neutral
Becton Dickinson's overall stock score reflects a solid financial foundation with strong revenue and cash flow management. However, technical indicators show bearish trends, and valuation metrics suggest the stock is relatively expensive. Earnings call insights and strategic business separation plans provide a mixed outlook, with both opportunities and challenges ahead.
Positive Factors
Business Restructuring
The planned separation of the Biosciences and Diagnostic solutions business could potentially create more value, with completion expected in fiscal year 2026.
Margin Performance
BDX's gross margin of 54.9% surpassed consensus expectations, driven by the BD Excellence operating system.
Negative Factors
Guidance and Forecasts
The company has lowered its guidance for fiscal year 2025 organic sales growth due to difficult market conditions and tariff uncertainties.
Market Valuation
The level of organic growth is at the low-end of MedTech, implying the market will ascribe a lower valuation to the stock.
Revenue Performance
Becton, Dickinson and Co. reported lower-than-expected revenue for the fiscal second quarter, indicating a challenging operating environment.

Becton Dickinson (BDX) vs. S&P 500 (SPY)

Becton Dickinson Business Overview & Revenue Model

Company DescriptionBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
How the Company Makes MoneyBecton Dickinson (BDX) generates revenue primarily through the sale of its medical technology products and services. The company segments its operations into three main divisions: BD Medical, BD Life Sciences, and BD Interventional, each contributing to its revenue streams. BD Medical, the largest segment, provides products such as syringes, needles, intravenous catheters, and infusion pumps, crucial for medication delivery and management. BD Life Sciences generates income through products used in specimen collection, diagnostic testing, and laboratory research, including automated diagnostic systems and assays. BD Interventional focuses on minimally invasive surgical instruments and solutions for disease management. BD also benefits from strategic partnerships, collaborations, and long-term contracts with healthcare providers, institutions, and governments, enhancing its market presence and ensuring a steady revenue flow. The company's global reach and diversified product portfolio help mitigate risks associated with market fluctuations and regulatory changes, ensuring a robust revenue model.

Becton Dickinson Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes income from different business units, highlighting which segments drive growth and profitability, and identifying areas of strategic focus or potential risk.
Chart InsightsBecton Dickinson's Medical segment shows strong recovery, with a notable upward trend since 2022, driven by strategic investments in Pharm Systems and Alaris. However, the Life Sciences segment faces headwinds from reduced global research funding, impacting growth. Despite these challenges, BD's strategic focus on U.S. manufacturing and product innovations, like Phasix, aims to bolster future performance. The earnings call highlighted a 6% revenue growth, though organic growth lagged at 0.9%, reflecting market pressures, particularly in China and Diagnostics, which could temper near-term optimism.
Data provided by:Main Street Data

Becton Dickinson Financial Statement Overview

Summary
Becton Dickinson maintains a commendable financial position with strong revenue growth, stable margins, and solid equity backing. The company demonstrates effective cash flow management, ensuring liquidity and operational efficiency. While there are minor areas of concern, such as increasing leverage and slightly declining net profit margins, the overall financial health is sound, providing a stable foundation for future growth.
Income Statement
85
Very Positive
Becton Dickinson shows strong financial performance with a consistent revenue growth trend from $17.12B in 2020 to $20.87B TTM. Gross Profit Margin is healthy, maintaining above 44% consistently, and the Net Profit Margin is stable, though slightly decreased to 7.18% TTM from 8.45% in 2021. EBIT and EBITDA margins demonstrate operational efficiency despite slight declines. Overall, the income statement reflects robust revenue growth and solid profitability, though there is room for improving net margins.
Balance Sheet
78
Positive
The balance sheet displays a strong equity position with $54.47B in stockholders' equity as of TTM, providing a high Equity Ratio of 100% due to total liabilities being restated. The Debt-to-Equity Ratio is moderate, reflecting reasonable leverage but has increased from 0.75 in 2020 to 0.34 TTM. ROE has been consistent but slightly decreased recently, indicating stable returns on equity. The company's solid equity base and manageable leverage suggest financial stability, but increasing net debt warrants monitoring.
Cash Flow
82
Very Positive
Cash flow analysis reveals strong operating cash flows, with $3.30B TTM, and substantial free cash flows, despite a decline from $3.42B in 2021 to $2.59B TTM. The Free Cash Flow to Net Income Ratio remains favorable, highlighting efficient cash conversion. The Operating Cash Flow to Net Income Ratio is robust, ensuring liquidity. Although there are fluctuations, the overall cash flow position is strong, supporting operational and strategic investments.
Breakdown
Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income StatementTotal Revenue
20.18B19.37B18.87B20.25B17.12B
Gross Profit
9.13B8.17B8.48B9.43B7.58B
EBIT
2.40B2.11B2.28B2.80B1.48B
EBITDA
4.82B4.28B4.29B4.25B2.97B
Net Income Common Stockholders
1.71B1.48B1.78B2.09B874.00M
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.16B1.42B1.01B2.29B2.85B
Total Assets
57.29B52.78B52.93B53.87B54.01B
Total Debt
20.11B15.88B16.07B17.61B17.93B
Net Debt
18.39B14.46B15.06B15.33B15.11B
Total Liabilities
31.40B26.98B27.63B30.19B30.24B
Stockholders Equity
25.89B25.80B25.30B23.68B23.77B
Cash FlowFree Cash Flow
3.07B2.12B1.66B3.42B2.73B
Operating Cash Flow
3.80B2.99B2.63B4.65B3.54B
Investing Cash Flow
-5.51B-716.00M-3.23B-1.88B-1.23B
Financing Cash Flow
2.09B-1.96B-591.00M-3.31B22.00M

Becton Dickinson Technical Analysis

Technical Analysis Sentiment
Negative
Last Price168.78
Price Trends
50DMA
216.08
Negative
100DMA
223.55
Negative
200DMA
227.77
Negative
Market Momentum
MACD
-8.85
Positive
RSI
21.42
Positive
STOCH
33.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDX, the sentiment is Negative. The current price of 168.78 is below the 20-day moving average (MA) of 199.76, below the 50-day MA of 216.08, and below the 200-day MA of 227.77, indicating a bearish trend. The MACD of -8.85 indicates Positive momentum. The RSI at 21.42 is Positive, neither overbought nor oversold. The STOCH value of 33.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDX.

Becton Dickinson Risk Analysis

Becton Dickinson disclosed 22 risk factors in its most recent earnings report. Becton Dickinson reported the most risks in the “Macro & Political” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Becton Dickinson Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
RMRMD
85
Outperform
$35.18B26.9425.81%0.88%9.54%37.23%
WSWST
74
Outperform
$15.11B33.0217.42%0.39%-1.14%-16.35%
COCOO
71
Outperform
$16.46B39.805.25%7.15%41.96%
BDBDX
68
Neutral
$48.37B28.045.97%2.35%5.84%15.12%
66
Neutral
$12.15B17.1411.77%1.75%50.25%
52
Neutral
$5.36B3.88-42.93%2.87%17.85%1.45%
BABAX
51
Neutral
$15.75B136.07-9.24%3.00%-20.17%-138.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BDX
Becton Dickinson
168.78
-63.74
-27.41%
BAX
Baxter International
30.71
-4.85
-13.64%
COO
Cooper Co
82.30
-10.10
-10.93%
HOLX
Hologic
54.16
-21.77
-28.67%
RMD
Resmed
239.95
24.96
11.61%
WST
West Pharmaceutical Services
211.29
-154.18
-42.19%

Becton Dickinson Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q2-2025)
|
% Change Since: -18.50%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Neutral
The earnings call revealed a mixed performance for BD, with strong adjusted EPS growth and strategic investments being overshadowed by revenue challenges and external market pressures in Life Sciences, Diagnostics, and the China market. Tariff impacts further complicate the outlook.
Q2-2025 Updates
Positive Updates
Adjusted EPS Growth Exceeds Expectations
Despite revenue challenges, BD exceeded their adjusted EPS growth expectations, delivering $3.35 in Q2, representing a 5.7% year-over-year increase.
Strong Margin Performance
BD reported adjusted gross margins of 54.9%, which increased by 190 basis points year-over-year, supported by the BD Excellence program.
Significant U.S. Manufacturing Investment
BD announced plans to invest $2.5 billion in U.S. manufacturing over the next five years to strengthen their position and commitment to a resilient U.S. healthcare system.
Positive Product Launches and Innovations
BD launched several new products like Phasix ST Umbilical and is on track to launch the BD FACSDiscover A8, which have received positive feedback from pilot customers.
Negative Updates
Revenue Growth Below Expectations
Revenues grew 6% or 0.9% organic, below expectations, due to market dynamics in Life Sciences and lower-than-expected recovery in Diagnostics.
Challenges in Life Sciences and Diagnostics
Life Sciences faced reduced global research funding, impacting biosciences instrument sales, while Diagnostics saw softness in the blood culture business.
China Market Decline
BD experienced a double-digit decrease in China sales due to volume-based procurement and ongoing research spending pressure.
Impact of Tariffs
BD expects $90 million in tariff expenses for FY '25, which will impact adjusted EPS by approximately $0.25, predominantly in Q4.
Company Guidance
During BD's Second Fiscal Quarter 2025 Earnings Call, the company provided guidance indicating a revised expectation for organic revenue growth of 3% to 3.5% for the full fiscal year, down from previous projections due to market dynamics impacting the Life Sciences and Diagnostics segments. BD reported Q2 revenue growth of 6%, or 0.9% organically, and an adjusted gross margin of 54.9%, which increased by 190 basis points year-over-year. Despite these challenges, BD exceeded its adjusted EPS growth expectations, delivering an EPS of $3.35, reflecting a 5.7% increase. The company is undertaking strategic actions to reaccelerate organic sales growth, including investments in its Pharm Systems, Alaris, PureWick, and Phasix product lines. Additionally, BD is actively mitigating the impacts of tariffs, estimating a $90 million tariff expense for FY '25, and has committed to a $2.5 billion investment in U.S. manufacturing over the next five years.

Becton Dickinson Corporate Events

Executive/Board Changes
Gregory J. Hayes Joins Becton Dickinson Board
Neutral
Mar 27, 2025

On March 26, 2025, Gregory J. Hayes was elected to the Board of Directors of Becton Dickinson, expanding the Board from eleven to twelve members. Hayes will serve on the Audit Committee and the Compensation and Human Capital Committee, and his appointment reflects BD’s adherence to corporate governance principles, potentially strengthening its board’s oversight capabilities.

Business Operations and StrategyFinancial Disclosures
Becton Dickinson Announces Strategic Business Separation Plan
Positive
Feb 5, 2025

On February 5, 2025, BD announced its plan to separate its Biosciences and Diagnostic Solutions business from the rest of the company, aiming for completion by fiscal 2026, pending various approvals. In its fiscal 2025 first quarter results, BD reported strong financial performance with a revenue increase of 9.8% to $5.2 billion and EPS growth, alongside plans to unlock value through strategic separation and enhance its focus on innovation and growth in respective markets.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.